Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Biofrontera (BFRI) EBIAT (2020 - 2025)

Biofrontera has reported EBIAT over the past 6 years, most recently at $5.6 million for Q4 2025.

  • For Q4 2025, EBIAT rose 504.01% year-over-year to $5.6 million; the TTM value through Dec 2025 reached -$10.5 million, up 40.67%, while the annual FY2025 figure was -$10.5 million, 40.67% up from the prior year.
  • EBIAT for Q4 2025 was $5.6 million at Biofrontera, up from -$6.6 million in the prior quarter.
  • Over five years, EBIAT peaked at $5.6 million in Q4 2025 and troughed at -$16.0 million in Q3 2021.
  • A 5-year average of -$4.3 million and a median of -$3.9 million in 2021 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: tumbled 7188.94% in 2021 and later skyrocketed 504.01% in 2025.
  • Year by year, EBIAT stood at -$14.5 million in 2021, then surged by 80.8% to -$2.8 million in 2022, then soared by 226.61% to $3.5 million in 2023, then tumbled by 139.59% to -$1.4 million in 2024, then skyrocketed by 504.01% to $5.6 million in 2025.
  • Business Quant data shows EBIAT for BFRI at $5.6 million in Q4 2025, -$6.6 million in Q3 2025, and -$5.3 million in Q2 2025.